JLJong Won Lee

Jong Won Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jong Won Lee has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Solam Lee

    Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea

    2 shared publications
  • Bo‐Kyung Kim

    Department of Dermatology Yonsei University Wonju College of Medicine Wonju Republic of Korea

    1 shared publication
  • Hanil Lee

    Department of Dermatology and Institute of Hair and Cosmetic Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea

    1 shared publication
  • Hee Seok Seo

    Department of Dermatology Yonsei University Wonju College of Medicine Wonju Republic of Korea

    1 shared publication
  • Ji Hae Lee

    Department of Dermatology, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 16247, Republic of Korea

    1 shared publication
  • Jong Cheol Shon

    BK21 FOUR Community‐Based Intelligent Novel Drug Discovery Education Unit College of Pharmacy and Research Institute of Pharmaceutical Sciences Kyungpook National University Daegu Republic of Korea

    1 shared publication

Latest Publications

  • Epidemiology and comorbidity of hidradenitis suppurativa in Korea for 17 years: A nationwide population‐based cohort study

    by Jong Won Lee, Yeon‐Woo Heo, Ji Hae Lee, Solam Lee

    Hidradenitis suppurativa (HS) is associated with various metabolic and autoimmune diseases. The epidemiology has been analyzed in various studies worldwide. However, epidemiological data on HS for Asian populations are limited. This study aimed to analyze the change in the prevalence and incidence of HS over 17 years in South Korea using the Korean National Health Insurance Service (NHIS) database. This study also evaluated the comorbidities in patients with HS. Population‐based data from the NHIS database of Korea were obtained between January 2003 and December 2019. Odds ratios were estimated to determine the association between comorbidities and HS during the study period. Hazard ratios for the risk of incident comorbidities in patients with HS were obtained using the multivariable Cox proportional hazard analysis. This study included 45 511 patients with HS and 910 220 controls matched for age, sex, insurance type, and income level. The incidence rate of HS per 1 000 000 person‐years in Korea increased from 11.69 in 2003 to 78.78 in 2019. The annual prevalence per 1 000 000 people also increased from 34.68 in 2003 to 140.10 in 2019, showing a similar trend. Many comorbidities, including atopic, metabolic and end‐organ, autoimmune/inflammatory, and psychiatric diseases were associated with HS at baseline. In many diseases, the risk of incident comorbidities in patients with HS was higher than that in controls. The incidence and prevalence of HS in Korea have increased over the past 17 years. Various comorbidities, including allergic diseases, hypertension, diabetes mellitus, dyslipidemia, myocardial infarction, chronic hepatitis and cirrhosis, chronic kidney disease, inflammatory bowel diseases, rheumatoid arthritis, vitamin D deficiency, and psychiatric diseases, were associated with HS. Physicians need to keep in mind and closely monitor these comorbidities in patients with HS.


  • Open Access

    Various Applications of Purse-String Suture and Its Cosmetic Outcome in Cutaneous Surgical Defects

    by Sujin Park, Yeongjoo Oh, Jong Won Lee, Sooyie Choi, Kyoung Ae Nam, Mi Ryung Roh, Kee Yang Chung

    Park S, et al. Ann Dermatol. 2023 Mar;35:e22. https://doi.org/10.5021/ad.21.263


  • Open Access

    Relationship of Hair Regrowth Pattern in Alopecia Areata Patches According to DIMT Classification with Treatment Modalities and Patch Size: A Retrospective Cross-Sectional Analysis

    by Sung Ha Lim, Hanil Lee, Solam Lee, Jong Won Lee, Sang-Hoon Lee, Won-Soo Lee

    Lim SH, et al. Ann Dermatol. 2022 Feb;34(1):1-6. https://doi.org/10.5021/ad.2022.34.1.1


  • Decrease of ceramides with long‐chain fatty acids in psoriasis: Possible inhibitory effect of interferon gamma on chain elongation

    by Bo‐Kyung Kim, Jong Cheol Shon, Hee Seok Seo, Kwang‐Hyeon Liu, Jong Won Lee, Sung Ku Ahn, Seung Phil Hong

    Reportedly, decreases in fatty acid (FA) chain length of ceramide (CER) are associated with interferon‐γ (IFN‐γ), which shows increased expression in psoriasis. However, the underlying mechanism of this association remains unclear. Therefore, in this study, we aimed to clarify this association between FA chain length of CER, IFN‐γ, and the major transcriptional factors involving psoriasis. CER profiling according to FA chain length and class was performed in murine epidermis (n = 10 BALB/c mice topically treated with imiquimod, n = 10 controls) and human stratum corneum (SC) (n = 12 psoriasis, n = 11 controls). The expression of lipid synthetic enzymes, including elongases (ELOVLs), in murine epidermis was also measured using RT‐PCR. Furthermore, the association of IFN‐γ with various enzymes and transcription factors involved in the generation of long‐chain CERs was also investigated using in vitro keratinocyte. A significant decrease in the percentage of long‐chain CERs was observed in psoriasis‐like murine epidermis and human psoriatic SC. Additionally, the expression levels of ELOVL1, ELOVL4, and ceramide synthase3 (CerS3) were significantly decreased in psoriasis‐like murine epidermis and IFN‐γ‐treated keratinocyte. There was also a significant decrease in the expression of transcriptional factors, including peroxisome proliferator‐activated receptor (PPAR), in IFN‐γ treated keratinocyte. Thus, it could be suggested that IFN‐γ may regulate ELOVL and CerS levels by down‐regulating the transcriptional factors. Additionally, given the possible involvement of PPARs or liver X receptor agonist in the CER elongation process, they may serve as potential therapeutic agents for lengthening the CER FAs in psoriasis.